Ascentage Pharma announced that lisaftoclax, a novel Bcl-2 inhibitor, has been cleared by the US FDA to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were previously treated with BTKi.
[Ascentage Pharma]